This early-phase study tests an experimental oral drug called AUTX-703 in about 34 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose…
Phase: PHASE1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 04:27 UTC